|
[1]
|
中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版) [J]. 协和医学杂志, 2024, 15(3): 532-559.
|
|
[2]
|
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
王裕新, 潘凯枫, 李文庆. 2022全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2024, 10(3):1-16.
|
|
[4]
|
戴靖宜, 蒋敬庭. 肝细胞肝癌肿瘤标志物诊断的新进展[J]. 诊断学理论与实践, 2023, 22(5): 486-493.
|
|
[5]
|
Yang, J.D., Hainaut, P., Gores, G.J., Amadou, A., Plymoth, A. and Roberts, L.R. (2019) A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management. Nature Reviews Gastroenterology & Hepatology, 16, 589-604. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
路丽霞, 王荣琦. 原发性肝癌基层筛查与健康监测管理的研究进展[J]. 中国全科医学, 2023, 26(36): 4505-4509.
|
|
[7]
|
Zhou, H. and Song, T. (2021) Conversion Therapy and Maintenance Therapy for Primary Hepatocellular Carcinoma. BioScience Trends, 15, 155-160. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
丁晓毅, 王征, 石洁, 等. 中国肝癌多学科综合治疗专家共识[J]. 临床肝胆病杂志, 2021, 37(2): 278-285.
|
|
[9]
|
赵荣策, 韦玮, 李少华, 等. 肝动脉灌注化疗在肝癌围手术期的应用及研究进展[J]. 中国肿瘤外科杂志, 2022, 14(2): 105-110.
|
|
[10]
|
Zhang, W., Wu, L., Chen, L., Sun, T., Ren, Y., Sun, B., et al. (2022) The Efficacy of Drug-Eluting Bead or Conventional Transarterial Chemoembolization plus Apatinib for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Scientific Reports, 12, Article No. 5725. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
张大闯, 马富权, 马富平, 等. 载药微球与传统C-TACE在治疗乏血供型原发性肝癌中的临床疗效对比[J]. 现代消化及介入诊疗, 2021, 26(6): 689-692.
|
|
[12]
|
Han, T., Yang, X., Zhang, Y., Li, G., Liu, L., Chen, T., et al. (2019) The Clinical Safety and Efficacy of Conventional Transcatheter Arterial Chemoembolization and Drug-Eluting Beads-Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Meta-analysis. BioScience Trends, 13, 374-381. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Ayyub, J., Dabhi, K.N., Gohil, N.V., Tanveer, N., Hussein, S., Pingili, S., et al. (2023) Evaluation of the Safety and Efficacy of Conventional Transarterial Chemoembolization (cTACE) and Drug-Eluting Bead (DEB)-TACE in the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review. Cureus, 15, e41943. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Chen, C., Liu, T., Shao, Y., Liu, K., Liang, P. and Lin, Z. (2021) Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma. International Journal of Molecular Sciences, 22, Article 12880. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Guo, W., Gao, J., Zhuang, W., Wu, Z., Li, B. and Chen, S. (2019) Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined with Transarterial Embolization for Unresectable Hepatocellular Carcinoma: A Propensity Score‐Matching Cohort Study. JGH Open, 4, 477-483. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
杨俊, 印于, 张申, 等. HAIC序贯TAE治疗不可切除肝细胞癌的安全性和有效性[J]. 介入放射学杂志, 2023, 32(3): 229-232.
|
|
[17]
|
Liu, B., Gao, S., Zhu, X., Guo, J., Kou, F., Liu, S., et al. (2021) Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score‐Matched Analysis. BioMed Research International, 2021, Article ID: 6670367. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
夏银锋, 陈红, 涂兵. 经动脉化疗栓塞(TACE)联合经动脉灌注化疗(HAIC)对比单纯TACE治疗不可切除肝癌的疗效及安全性[J]. 临床医学进展, 2023, 13(5): 8156-8162.
|
|
[19]
|
Huang, J., Huang, W., Zhan, M., Guo, Y., Liang, L., Cai, M., et al. (2021) Drug-Eluting Bead Transarterial Chemoembolization Combined with Folfox-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 8, 1445-1458. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Nakano, M.M., Yamamoto, A., Nishida, N., Hamuro, M., Hamamoto, S., Jogo, A., et al. (2019) Risk Factors for Local Recurrence of Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization with Drug-Eluting Beads (DEB-TACE). Japanese Journal of Radiology, 37, 543-548. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Zhang, X., Lin, X., Qiu, H. and Peng, Z. (2019) An Investigation of Efficacy, Safety, and Prognostic Factors of Drug‐eluting Beads‐Transarterial Chemoembolization Operation with Callispheres® Microspheres in Treating Chinese Hepatocellular Carcinoma Patients. Journal of Clinical Laboratory Analysis, 33, e22975. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Duan, R., Gong, F., Wang, Y., Huang, C., Wu, J., Hu, L., et al. (2023) Transarterial Chemoembolization (TACE) plus Tyrosine Kinase Inhibitors versus TACE in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. World Journal of Surgical Oncology, 21, Article No. 120. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Mou, L., Tian, X., Zhou, B., Zhan, Y., Chen, J., Lu, Y., et al. (2021) Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials. Frontiers in Oncology, 11, Article 752725. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Ayati, A., Moghimi, S., Salarinejad, S., Safavi, M., Pouramiri, B. and Foroumadi, A. (2020) A Review on Progression of Epidermal Growth Factor Receptor (EGFR) Inhibitors as an Efficient Approach in Cancer Targeted Therapy. Bioorganic Chemistry, 99, Article ID: 103811. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Huang, L., Jiang, S. and Shi, Y. (2020) Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001-2020). Journal of Hematology & Oncology, 13, Article No. 143. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Kudo, M., Ueshima, K., Ikeda, M., Torimura, T., Tanabe, N., Aikata, H., et al. (2019) Randomised, Multicentre Prospective Trial of Transarterial Chemoembolisation (TACE) plus Sorafenib as Compared with TACE Alone in Patients with Hepatocellular Carcinoma: TACTICS Trial. Gut, 69, 1492-1501. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Kudo, M., Ueshima, K., Ikeda, M., Torimura, T., Tanabe, N., Aikata, H., et al. (2022) Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer, 11, 354-367. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Ding, X., Sun, W., Li, W., Shen, Y., Guo, X., Teng, Y., et al. (2021) Transarterial Chemoembolization plus Lenvatinib versus Transarterial Chemoembolization Plus Sorafenib as First‐Line Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Prospective Randomized Study. Cancer, 127, 3782-3793. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Kudo, M., Finn, R.S., Qin, S., Han, K., Ikeda, K., Piscaglia, F., et al. (2018) Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. The Lancet, 391, 1163-1173. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y., Bodoky, G., et al. (2017) Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet, 389, 56-66. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Abou-Alfa, G.K., Meyer, T., Cheng, A., El-Khoueiry, A.B., Rimassa, L., Ryoo, B., et al. (2018) Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. New England Journal of Medicine, 379, 54-63. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Kelley, R., Ryoo, B., Merle, P., Park, J., Bolondi, L., Chan, S.L., et al. (2020) Second-line Cabozantinib after Sorafenib Treatment for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the Phase 3 CELESTIAL Trial. ESMO Open, 5, e000714. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Zhu, A.X., Park, J.O., Ryoo, B., Yen, C., Poon, R., Pastorelli, D., et al. (2015) Ramucirumab versus Placebo as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma Following First-Line Therapy with Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial. The Lancet Oncology, 16, 859-870. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Zhu, A.X., Kang, Y., Yen, C., Finn, R.S., Galle, P.R., Llovet, J.M., et al. (2019) Ramucirumab after Sorafenib in Patients with Advanced Hepatocellular Carcinoma and Increased Α-Fetoprotein Concentrations (REACH-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 20, 282-296. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Kaufman, H.L., Atkins, M.B., Subedi, P., Wu, J., Chambers, J., Joseph Mattingly, T., et al. (2019) The Promise of Immuno-Oncology: Implications for Defining the Value of Cancer Treatment. Journal for ImmunoTherapy of Cancer, 7, 129. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Leone, P., Solimando, A.G., Fasano, R., Argentiero, A., Malerba, E., Buonavoglia, A., et al. (2021) The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines, 9, Article 532. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Zeng, Z., Yang, B. and Liao, Z. (2020) Current Progress and Prospect of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma (Review). Oncology Letters, 20, Article No. 45. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
El-Khoueiry, A.B., Sangro, B., Yau, T., Crocenzi, T.S., Kudo, M., Hsu, C., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (Checkmate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Zhu, A.X., Finn, R.S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., et al. (2018) Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial. The Lancet Oncology, 19, 940-952. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Qin, S., Ren, Z., Meng, Z., Chen, Z., Chai, X., Xiong, J., et al. (2020) Camrelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma: A Multicentre, Open-Label, Parallel-Group, Randomised, Phase 2 Trial. The Lancet Oncology, 21, 571-580. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Marinelli, B., Kim, E., D’Alessio, A., Cedillo, M., Sinha, I., Debnath, N., et al. (2022) Integrated Use of PD-1 Inhibition and Transarterial Chemoembolization for Hepatocellular Carcinoma: Evaluation of Safety and Efficacy in a Retrospective, Propensity Score-Matched Study. Journal for ImmunoTherapy of Cancer, 10, e004205. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Cucarull, B., Tutusaus, A., Rider, P., Hernáez-Alsina, T., Cuño, C., García de Frutos, P., et al. (2022) Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers, 14, Article 621. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Liu, Z., Tu, K., Wang, Y., Yao, B., Li, Q., Wang, L., et al. (2017) Hypoxia Accelerates Aggressiveness of Hepatocellular Carcinoma Cells Involving Oxidative Stress, Epithelial-Mesenchymal Transition and Non-Canonical Hedgehog Signaling. Cellular Physiology and Biochemistry, 44, 1856-1868. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Han, Z., Yang, F., Zhang, Y., Wang, J., Ni, Q., Zhu, H., et al. (2022) Prognostic Efficacy and Prognostic Factors of TACE plus TKI with ICIs for the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study. Frontiers in Oncology, 12, Article 1029951. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Long, Y., Huang, J., Liao, J., Zhang, D., Huang, Z., He, X., et al. (2023) Safety and Survival Outcomes of Liver Resection Following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma. Cancers, 15, Article 5878. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Feng, J., Liu, Z., Fu, Z., Chai, Z., Sun, J., Wang, K., et al. (2022) Efficacy and Safety of Transarterial Chemoembolization Plus Antiangiogenic-Targeted Therapy and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in the Real World. Frontiers in Oncology, 12, Article 954203. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Sun, T., Ren, Y., Sun, B., Chen, L., Zhu, L., Zhang, L., et al. (2023) The Feasibility of TACE Combined with TKIs plus PD-1 Antibody for Advanced HCC. Journal of Hepatocellular Carcinoma, 10, 447-457. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Yuan, Y., He, W., Yang, Z., Qiu, J., Huang, Z., Shi, Y., et al. (2023) TACE-HAIC Combined with Targeted Therapy and Immunotherapy versus TACE Alone for Hepatocellular Carcinoma with Portal Vein Tumour Thrombus: A Propensity Score Matching Study. International Journal of Surgery, 109, 1222-1230. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Huang, Z., Wu, Z., Zhang, L., Yan, L., Jiang, H. and Ai, J. (2024) The Safety and Efficacy of TACE Combined with HAIC, PD-1 Inhibitors, and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Frontiers in Oncology, 14, Article 1298122. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Li, L., He, J., Xie, Y.X., et al. (2022) A Retrospective Controlled Study of TACE-HAIC-Targeted-Immune Quadruple Therapy for Intermediate and Advanced-Stage Hepatocellular Carcinoma. Chinese Journal of Hepatology, 30, 939-946.
|
|
[51]
|
Pang, B., Zuo, B., Huang, L., You, X., Liu, T., Hao, J., et al. (2024) Real-world Efficacy and Safety of TACE-HAIC Combined with TKIs and PD-1 Inhibitors in Initially Unresectable Hepatocellular Carcinoma. International Immunopharmacology, 137, Article ID: 112492. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Liu, C., Li, T., He, J. and Shao, H. (2020) TACE Combined with Microwave Ablation Therapy vs. TACE Alone for Treatment of Early-and Intermediate-Stage Hepatocellular Carcinomas Larger than 5 Cm: A Meta-Analysis. Diagnostic and Interventional Radiology, 26, 575-583. [Google Scholar] [CrossRef] [PubMed]
|